Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma

ABSTRACT:

SUBMITTER: Tsang C 

PROVIDER: S-EPMC12297639 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature